• FirefoxInstall the new Firefox »
  •  Dow Down0.58% Nasdaq Down0.26%

    SIGA Technologies, Inc. (SIGA)

    2.44 Up 0.11(4.72%) Mar 4, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    SIGA Technologies, Inc.
    660 Madison Avenue
    Suite 1700
    New York, NY 10065
    United States - Map
    Phone: 212-672-9100
    Fax: 212-697-3130
    Website: http://www.siga.com

    Index Membership:N/A
    Full Time Employees:34

    Business Summary 

    SIGA Technologies, Inc. is engaged in the development and commercialization of pharmaceutical solutions for serious unmet medical needs and biothreats. The company’s lead product is Arestvyr, an orally administered antiviral drug that targets orthopoxviruses. It is also developing dengue antiviral and anti-arenavirus drug candidates, which are in pre-clinical stage. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York. On September 16, 2014, SIGA Technologies, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on SIGA Technologies, Inc.

    Corporate Governance 
    SIGA Technologies, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 1; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Eric A. Rose M.D., 64
    Exec. Chairman, Chief Exec. Officer and Member of National Biodefense Science Board
    Mr. Daniel J. Luckshire , 44
    Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
    Dr. Dennis E. Hruby Ph.D., 63
    Chief Scientific Officer and VP
    Mr. William J. Haynes II, 57
    Exec. VP and Gen. Counsel
    Doris McCarthy ,
    Director of Admin.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders